Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

NCT04702490 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH
NASH - Nonalcoholic Steatohepatitis
Type 2 Diabetes
Diabetes Type 2
Diabetes
Fatty Liver
Fatty Liver, Nonalcoholic
NAFLD

Interventions

DRUG: MET409 Active
DRUG: MET409 Placebo
DRUG: Empagliflozin

Sponsor

Metacrine, Inc.